McKesson Corporation vs Nasdaq Inc — how do they compare? McKesson Corporation trades at $824.51 (market cap $97.35B), while Nasdaq Inc trades at $90.73 (market cap $51.96B). The key difference: McKesson Corporation is the larger of the two by market cap, and Nasdaq Inc pays the higher dividend (1.22%). Which is the better fit depends on your goals.
| MCK | NDAQ | |
|---|---|---|
Market Cap | $97.35B | $51.96B |
Sector | Health | Financials |
52-Week High | $995.69 | $100.98 |
52-Week Low | $659.01 | $76.85 |
Enterprise Value | $101.98B | $59.02B |
Dividend Yield | 0.39% | 1.22% |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Nasdaq (NDAQ) trades at $92.00, up 0.39% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $105.60. Recent earnings beats and strong profitability margins, including a net income margin of 23.03%, highlight fundamental strength. The company continues to expand its non-trading businesses and execute strategic initiatives, as noted in recent financial media coverage.
The outlook for NDAQ is positive, driven by consistent earnings performance and strategic growth in market infrastructure. Key risks include market volatility sensitivity and high valuation multiples. Investors should weigh the robust analyst support against potential macroeconomic headwinds affecting exchange volumes.
Trailing returns across standard periods
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →